Eddy Lee Yip Hang
Chairman & Chief Executive Officer
Board of iXBiopharmaLtd.; current report-date roleThe business, the people and the ownership behind IX Biopharma.
Business overview
iX Biopharma is a specialty pharmaceutical company focused on repurposing drugs using proprietary delivery technologies. Its WaferiX and WaferlogiX platforms support sublingual drug delivery and the development of new therapeutic uses or dosage forms.
Listed security
Board & management
Fourcurrentdirectors and threeadditional senior managers are disclosed. Chairman/CEOEddyLee duplicatedinSeniorManagement is consolidated into one rolefact. FormerexternalCFOroles ofTeoJohn are not listedCompanyCFO.
Initial appointment/lastre-electiondates and committee roles are printed in the original biographies and retained in source quotes; no report-year appointment date inferred.
Chairman & Chief Executive Officer
Board of iXBiopharmaLtd.; current report-date roleLead Independent Director
Board of iXBiopharmaLtd.; current report-date roleIndependent Non-Executive Director
Board of iXBiopharmaLtd.; current report-date roleNon-Executive Director
Board of iXBiopharmaLtd.; current report-date roleChief Operating Officer & Chief Medical Officer
Senior Management; Group pharmaceutical and nutraceutical development and AustralianGMPfacilityChief Commercial Officer
Senior Management; GroupglobalcommercialstrategiesChief Financial Officer
Senior Management; Group accounting/financial/tax/investment mattersRoles listed in ANNUAL REPORT 2026; current appointments are not independently verified.
Holdings
Two substantialholders and20listedlargestholders retain direct/deemed/nominee capacities. EddyLee spouse-deemed21,848,722 is separatefrom direct227,578,834; OCBCdeemed55,153,800 consists of BOSTL1,900,000 andLGI53,253,800 peroriginal footnotes; these are not extra nominee/additionalholdings.
Shareholderregisterdate11September2026 is laterthan financialpositiondate30June2026; registercapital$127,178,000/fullshares1,093,315,474 are not substituted for balance-datecapital$125,672thousand.
Originaltop20subtotal75.18%equals sumof20roundedholderpercentages, while821,885,822/1,093,315,474 rounds75.17%. Bothoriginal andseparate calculationretained; source doesnot state subtotalroundingmethod.
Direct interest 227,578,834 shares (20.82%); deemed interest 21,848,722 shares (2.00%).
Substantial shareholder direct/deemed interests,11September2026Direct interest: – (–); deemed interest: 55,153,800 shares (5.04%).
Substantial shareholder direct/deemed interests,11September20261,093,315,474 ordinary shares; Nil treasury shares; one vote per ordinary share; issued and fully paid-up capital $127,178,000
Original shareholder statistics as at11September202675.18%Total interest
70.72%
Original shareholder statistics as at11September2026Total interests include direct and deemed holdings and may overlap across holders. These percentages should not be added together.
Registered holdings, including nominees and depositories; these do not establish ultimate beneficial ownership. As reported at 2026-09-11 · PDF p. 97
| Registered holder | Interest | Shares / units | Source |
|---|---|---|---|
| EDDY LEE YIP HANG | 227,578,834 shares; 20.82% of shares. | PDF p. 972026-09-11 | |
| CGS INTERNATIONAL SECURITIES SINGAPORE PTE. LTD. | 94,599,048 shares; 8.65% of shares. | PDF p. 972026-09-11 | |
| PHILLIP SECURITIES PTE LTD | 84,635,938 shares; 7.74% of shares. | PDF p. 972026-09-11 | |
| CITIBANK NOMINEES SINGAPORE PTE LTD | 81,478,856 shares; 7.45% of shares. | PDF p. 972026-09-11 | |
| DBS NOMINEES PTE LTD | 50,756,409 shares; 4.64% of shares. | PDF p. 972026-09-11 | |
| HSBC (SINGAPORE) NOMINEES PTE LTD | 47,994,161 shares; 4.39% of shares. | PDF p. 972026-09-11 | |
| OCBC SECURITIES PRIVATE LTD | 42,985,950 shares; 3.93% of shares. | PDF p. 972026-09-11 | |
| TANG CHOY LENG, JANE MRS JANE LEE CHOY LENG | 21,848,722 shares; 2.00% of shares. | PDF p. 972026-09-11 | |
| MOOMOO FINANCIAL SINGAPORE PTE. LTD. | 21,537,083 shares; 1.97% of shares. | PDF p. 972026-09-11 | |
| MAYBANK SECURITIES PTE. LTD. | 19,977,412 shares; 1.83% of shares. | PDF p. 972026-09-11 | |
| WETWATERS 8 (S) PTE LTD | 16,650,270 shares; 1.52% of shares. | PDF p. 972026-09-11 | |
| CHAN HWEE HOON | 15,487,234 shares; 1.42% of shares. | PDF p. 972026-09-11 | |
| SEAH BOON LOCK | 15,045,869 shares; 1.38% of shares. | PDF p. 972026-09-11 | |
| RAFFLES NOMINEES (PTE) LIMITED | 15,044,098 shares; 1.38% of shares. | PDF p. 972026-09-11 | |
| ALBERT HO SHING TUNG | 13,200,219 shares; 1.21% of shares. | PDF p. 972026-09-11 | |
| SNG BENG HOCK MICHAEL | 12,825,000 shares; 1.17% of shares. | PDF p. 972026-09-11 | |
| MERRILL LYNCH (SINGAPORE) PTE LTD | 11,866,600 shares; 1.09% of shares. | PDF p. 972026-09-11 | |
| HARDEEP KAUR D/O HARDIAL SINGH | 11,518,639 shares; 1.05% of shares. | PDF p. 972026-09-11 | |
| JASVINPAL SINGH NARULLA | 8,648,700 shares; 0.79% of shares. | PDF p. 972026-09-11 | |
| ABN AMRO CLEARING BANK N.V. | 8,206,780 shares; 0.75% of shares. | PDF p. 972026-09-11 | |
Group structure
Twelve subsidiaries with full activities,country/businessincorporation and explicit parentpaths: sevenheldbyCompany, threebyEntityHealthLtd, onebyEntityHealth(China)CompanyLtd andonebyiXBiopharmaEuropeLimited. Original2026/2025immediate-holder equityholding is100/100 for each; no undisclosed effectivepercentage is inferred.
Original audits: (a)BDO LLP forGroupfinancials without statutoryaudits required locally;(b)BDO LLP forGroupfinancials;(c)S.Y.Wong;(d)LigoPharma dormant;(e)BDO LLP Singapore;(f)ShenzhenPengrun;(g)Cleary&CompanyIreland. Sourcefootnotemarkers/full originalnotes retained.
| Company | Market | Ownership interest |
|---|---|---|
| iX Biopharma Pty LtdSubsidiary; held by Company; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred | Country: Australia; activities: Research and experimental development; 100%; 100% | |
| iX Syrinx Pty Ltd (“Syrinx”)Subsidiary; held by Company; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred | Country: Australia; activities: Manufacturing and sale of pharmaceutical and nutraceutical products; 100%; 100% | |
| Arrow Property TrustSubsidiary; held by Company; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred | Country: Australia; activities: Owner of an industrial property that is leased exclusively to Syrinx; 100%; 100% | |
| Kaizen Manufacturing Pty LtdSubsidiary; held by Company; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred | Country: Australia; activities: Trustee of Arrow Property Trust; 100%; 100% | |
| Entity Health LtdSubsidiary; held by Company; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred | Country: Hong Kong; activities: Promotion and marketing of nutraceutical products; 100%; 100% | |
| iX Biopharma Europe LimitedSubsidiary; held by Company; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred | Country: Ireland; activities: Promotion and marketing of pharmaceutical and nutraceutical products; 100%; 100% | |
| Ligo Pharma LimitedSubsidiary; held by Company; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred | Country: Cayman Islands; activities: Investment holding company; 100%; 100% | |
| Entity Health Pte LtdSubsidiary; held by Entity Health Ltd; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred | Country: Singapore; activities: Promotion and marketing of nutraceutical products; 100%; 100% | |
| Entity Health (China) Company LtdSubsidiary; held by Entity Health Ltd; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred | Country: Hong Kong; activities: Investment holding company; 100%; 100% | |
| Entity Health Pty LtdSubsidiary; held by Entity Health Ltd; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred | Country: Australia; activities: Promotion and marketing of nutraceutical products; 100%; 100% | |
| Entity Health (Shanghai) Co LtdSubsidiary; held by Entity Health (China) Company Ltd; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred | Country: China; activities: Promotion and marketing of nutraceutical products; 100%; 100% | |
| Entity Health, Inc.Subsidiary; held by iX Biopharma Europe Limited; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred | Country: United States of America; activities: Promotion and marketing of pharmaceutical and nutraceutical products; 100%; 100% | |
Ownership interests and geographic information follow the annual report. Comparative years and footnote markers retain the report’s notation.
Senior executives
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Eddy Lee Yip Hang | Chairman & Chief Executive Officer | Senior Management | PDF p. 27 |
| Dr. Janakan Krishnarajah | Chief Operating Officer & Chief Medical Officer | Senior Management | PDF p. 27 |
| Eva Tan | Chief Commercial Officer | Senior Management | PDF p. 27 |
| Chew Sien Lup | Chief Financial Officer | Senior Management | PDF p. 27 |
| Jeremy Dalton | General Manager | Senior Management | PDF p. 28 |
| Dr. Iain Cook | Chief Scientist | Senior Management | PDF p. 28 |
| Dr. Stephen Lim | Chief Pharmacist | Senior Management | PDF p. 28 |
Extracted from ANNUAL REPORT 2026 and checked against the cited pages; see the original report for full context.
Related parties, people & properties
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Fee related to licensing to subsidiaries | 287 $'000 | Company transactions with subsidiaries, FY2026 (comparative 2025: 295) | PDF p. 93 |
| Purchases of inventories from subsidiaries | 96 $'000 | Company transactions with subsidiaries, FY2026 (comparative 2025: 12) | PDF p. 93 |
| Professional fee recharged to subsidiaries | 166 $'000 | Company transactions with subsidiaries, FY2026 (comparative 2025: 138) | PDF p. 93 |
| Key management personnel compensation (total) | 4,372 $'000 | Group and Company, 2026 (comparative 2025: 2,216) | PDF p. 93 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Capital commitments | $73,000 | Group, at balance sheet date 30 June 2026 (2025: $3,000) | PDF p. 86 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Eddy Lee Yip Hang | $1,965.3 | FY2026, $'000 total; Fees – ; Fixed Salary 19%; Bonus 5%; Other Benefits 50%; Share-based 26% | PDF p. 36 |
| Albert Ho Shing Tung | $83.5 | FY2026, $'000 total; Fees 100% | PDF p. 36 |
| Patrick Donald Davies | $89.5 | FY2026, $'000 total; Fees 100% | PDF p. 36 |
| Teo Woon Keng John | $83.5 | FY2026, $'000 total; Fees 100% | PDF p. 36 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Emergency Use Authorization Declaration | 3 September 2026, the US Government published an | After the close of FY2026 | PDF p. 9 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Chairman's closing statement | Our singular focus now is execution. | Chairman & CEO statement, FY2026 | PDF p. 9 |
Extracted from ANNUAL REPORT 2026 and checked against the cited pages; see the original report for full context.
Corporate information